Orexo Falls as Much as 20% After J&J Drug Research Deal Canceled

Orexo AB (ORX) fell as much as 20 percent, the most since November 2005, in Stockholm trading after saying drug research and licensing deals with Johnson & Johnson (JNJ) subsidiaries had been terminated. The shares traded down 4.1 kronor, or 15 percent, to 23.80 kronor at 9:15 a.m.

To contact the editor responsible for this story: Naomi Kresge at nkresge@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.